Tag Archives: Biohaven’s

Biohaven’s ambitious Nurtec ODT marketing strategy pays dividends with doctors in migraine market: analyst

Biohaven went all-in on marketing its added preventative indication for oral migraine med Nurtec. And now it’s reaping the rewards with doctors. Three months post-approval, 96% of neurologists were aware of the brand, while 65% are “highly familiar” with it, according to Spherix Global Insights’ postlaunch report. Nurtec easily bested bigger migraine players postlaunch familiarity including Amgen’s… Read More »